Sanofi, Medtronic join on diabetes drugs, devices

by The Associated Press

French drugmaker Sanofi and U.S. medical device manufacturer Medtronic Inc. have joined in a project to develop new combinations of drugs and devices for diabetes care.

The two major companies announced Saturday the "global strategic alliance," which they said was aimed at improving experience and results for people with diabetes around the world. The companies say the initial priorities will be developing drug-device combinations and providing care-management services to simplify .

Paris-based Sanofi has expertise in developing insulin drugs while Minneapolis-based Medtronic makes insulin pumps and devices for monitoring glucose to control blood sugar.

According to the World Health Organization, an estimated 347 million people worldwide have diabetes. In the U.S., about 30 million people have the disease.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Personalised treatment for stress-related diabetes

Oct 14, 2014

Researchers at Lund University in Sweden are testing a treatment for type 2 diabetes which targets the disease mechanism itself - and not just the symptoms. For the first time, knowledge about the individual patient's genetic ...

Sensors to simplify diabetes management

Oct 13, 2014

For many patients diagnosed with diabetes, treating the disease can mean a burdensome and uncomfortable lifelong routine of monitoring blood sugar levels and injecting the insulin that their bodies don't ...

Androgen receptor signaling tied to insulin resistance

Oct 09, 2014

(HealthDay)—Mouse models show tissue-specific androgen receptor (AR) signaling is involved in regulation of metabolism, which may explain the link between androgen deprivation therapy (ADT) and the development ...

User comments